BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28199478)

  • 1. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
    Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD
    JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
    Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
    Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
    Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
    Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
    Weingart J; Grossman SA; Carson KA; Fisher JD; Delaney SM; Rosenblum ML; Olivi A; Judy K; Tatter SB; Dolan ME
    J Clin Oncol; 2007 Feb; 25(4):399-404. PubMed ID: 17264335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
    Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
    Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
    Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
    Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
    Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
    Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
    Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
    Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
    JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
    Ryan CW; Dolan ME; Brockstein BB; McLendon R; Delaney SM; Samuels BL; Agamah ES; Vokes EE
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):634-9. PubMed ID: 16520986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
    Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
    J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable remission of folliculotropic mycosis fungoides achieved with a combined topical treatment with cytarabine and carmustine.
    Heisig M; Maj J; Szepietowski JC; Reich A
    Dermatol Ther; 2016; 29(1):15-8. PubMed ID: 26278921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
    Kim EJ; Mangold AR; DeSimone JA; Wong HK; Seminario-Vidal L; Guitart J; Appel J; Geskin L; Lain E; Korman NJ; Zeitouni N; Nikbakht N; Dawes K; Akilov O; Carter J; Shinohara M; Kuzel TM; Piette W; Bhatia N; Musiek A; Pariser D; Kim YH; Elston D; Boh E; Duvic M; Huen A; Pacheco T; Zwerner JP; Lee ST; Girardi M; Querfeld C; Bohjanen K; Olsen E; Wood GS; Rumage A; Donini O; Haulenbeek A; Schaber CJ; Straube R; Pullion C; Rook AH; Poligone B
    JAMA Dermatol; 2022 Sep; 158(9):1031-1039. PubMed ID: 35857290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides.
    MacArthur KM; Jariwala N; Kim EJ; Rook AH
    Acta Derm Venereol; 2017 Mar; 97(3):373-374. PubMed ID: 27868149
    [No Abstract]   [Full Text] [Related]  

  • 15. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
    Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
    Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine.
    Tserng KY; Ingalls ST; Boczko EM; Spiro TP; Li X; Majka S; Gerson SL; Willson JK; Hoppel CL
    J Clin Pharmacol; 2003 Aug; 43(8):881-93. PubMed ID: 12953345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
    Batts ED; Maisel C; Kane D; Liu L; Fu P; O'Brien T; Remick S; Bahlis N; Gerson SL
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):415-21. PubMed ID: 17354015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
    J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
    Quinn JA; Jiang SX; Carter J; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Threatt S; Friedman HS
    Clin Cancer Res; 2009 Feb; 15(3):1064-8. PubMed ID: 19188181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.
    Vieyra-Garcia P; Fink-Puches R; Porkert S; Lang R; Pöchlauer S; Ratzinger G; Tanew A; Selhofer S; Paul-Gunther S; Hofer A; Gruber-Wackernagel A; Legat F; Patra V; Quehenberger F; Cerroni L; Clark R; Wolf P
    JAMA Dermatol; 2019 May; 155(5):538-547. PubMed ID: 30892603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.